An observational study in Type 1 Diabetes (T1D), sponsored by University Hospital, Grenoble. Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by University Hospital, Grenoble · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble — 2 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · University Hospital, Grenoble.
Among the 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 18th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 5
First in 2003; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 35 is below the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 42 across the 11 interventional studies, 100 across the 7 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective, multicenter, descriptive cohort (RIPH3 study under the Jardé Act), STABILOOP study aims to describe whether BF may be an appropriate therapeutic option for the cohort of patients who are theoretically candidates for Islet transplantation, by describing Closed-Loop failures at 12 months in patients referred to an expert center for management of unstable diabetes.
Patients aged of minimum 18 years with Type 1 unstable diabetes, eligible to both Islet Transplant of Closed Loop treatement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Type 1 diabetic patients describing:
Exclusion Criteria:
Patients who choose te be treated by Closed-Loop in routine care
Patients who choose te be treated by Islet Graft in routine care
Describe Closed Loop (CL) failures at 12 months in patients referred to an expert center for management of unstable diabetes.
Proportion of patients on CL who have had in the year following the introduction of CL therapy : at least 2 severe hypoglycaemias (HS) with assistance from a third party or 1 life-threatening HS (coma or convulsion)
Time frame: 12 months
Assess quality of glycaemic control in patients treated with Closed Loop (CL) or Islet Graft (IG)
Quality of glycaemic control for CL \& IG patients : \- Data sensor (TIR-TBR-TAR \> Glycaemic Target 70-140 \& 70-180), reported as percentage of time.
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess the variation of the glycaemia management index in patients treated with Closed Loop (CL) or Islet Graft (IG)
Variation of glycaemia management index for CL \& IG patients : \- Data sensor GMI (%)
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess glucose variability in patients treated with Closed Loop (CL) or Islet Graft (IG)
glucose variability for CL \& IG patients : \- MAGE index
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess glycaemia variability in patients treated with Closed Loop (CL) or Islet Graft (IG)
Data sensor Glycaemia variability for CL \& IG patients: \- CV (%)
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess the level of mean glucose in patients treated with Closed Loop (CL) or Islet Graft (IG)
Level of blood glucose for CL \& IG patients : * Data sensor average daily blood glucose
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess hypoglycemia awareness in patients treated with Closed Loop (CL) or Islet Graft (IG)
Hypoglycemia awareness for CL \& IG patients : \- Clarke score every 3 months for 1 year then every 6 months for 3 years
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months for 1 year then every 6 months for 3 years
Assess balance between hypoglycaemia and hyperglycaemia in patients treated with Closed Loop (CL) or Islet Graft (IG)
Balance between hypoglycaemia and hyperglycaemia for CL \& IG patients : \- GRI glycaemic risk index
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess the evolution of insulin requirement in patients treated with Closed Loop (CL) or Islet Graft (IG)
Insulin requirement for CL \& IG patients : \- insulin doses (IU/kg/day)
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess glycaemia stability in patients treated with Closed Loop (CL) or Islet Graft (IG)
Glycaemia stability for CL \& IG patients : \- HbA1c (%)
Time frame: Quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years 1st IG, depending on the date of inclusion in the study.
Assess renal function in patients treated with Closed Loop (CL) or Islet Graft (IG)
Quality of renal function for CL \& IG patients : \- Creatininaemia (µmol/L) to estimate the glomerular filtration rate (mL/min/1.73m²)
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess occurence of sever diabetic related events in patients treated with Closed Loop (CL) or Islet Graft (IG)
For CL \& IG patients : \- sever hypoglycaemia (with assistance from a third party) / ketosis or ketoacidosis
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess the level of endogenous production of insulin in patients treated with Islet Graft (IG)
Level of C-peptide for IG patients : \- Fasting and stimulated C-peptide (nmol/L)
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess the quality of the Islet Graft (IG)
Quality of islet graft in IG patients : \- Graft function assessed by IGLS 2.0 score
Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.
Assess the antidiabetic management in patients treated with Islet Graft (IG)
Antidiabetic drug used in IG patients : \- Presence of antidiabetic drugs other than insulin (metformin, SLGT-2 inhibitor, GLP-1 analogues, DPP4 inhibitor, hypoglycaemic sulphonamides, glinides).
Time frame: Quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after 1st IG, depending on the date of inclusion in the study.
Assessing quality of life related to diabetes disease in patients treated with Closed Loop (CL) or Islet Graft (IG)
Describing quality of life questionnaires : DQOL (Diabetes Quality of Life Measure), score (0-100), higher scores = better quality of life
Time frame: Before CL/1st IG, and at 6, 12 and 24 months after CL/1st IG.
Assessing global quality of life in patients treated with Closed Loop (CL) or Islet Graft (IG)
Describing quality of life questionnaires : EQ-5D-5L (auto assessed health status questionnaire), score (0-1), higher scores = better health status
Time frame: Before CL/1st IG, and at 6, 12 and 24 months after CL/1st IG.
Assessing diabetes burden (diabetes-related emotional distress) in patients treated with Closed Loop (CL) or Islet Graft (IG)
Describing the burden of diabetes/questionnaires : T1-DDS (type 1 diabetes distress scale), score (28-168), higher scores = worse outcome
Time frame: Before CL/1st IG, and at 6, 12 and 24 months after CL/1st IG.
Assessing diabetes burden (fear of hypoglycemia) in patients treated with Closed Loop (CL) or Islet Graft (IG)
Describing the burden of diabetes: HFS (hypoglycemia fear score), score (0-132), higher scores = worse outcome
Time frame: Before CL/1st IG, and at 6, 12 and 24 months after CL/1st IG.
Assessing diabetes burden (impact and severity of fatigue) in patients treated with Closed Loop (CL) or Islet Graft (IG)
Describing the burden of diabetes/questionnaires : FSS (fatigue severity scale), score (9-63), higher scores = worse outcome
Time frame: Before CL/1st IG, and at 6, 12 and 24 months after CL/1st IG.
Assess overall patient satisfaction of patients treated with Closed Loop (CL) or Islet Graft (IG)
Describe patients' overall experience of their treatment modality(ies): \- DTSQ (diabetes treatment satisfaction questionnaire), score (0-36), higher scores = better treatment satisfaction
Time frame: Before CL/1st IG, then at 6, 12, 24 months post-CL or post 1st IG (or just before a change in treatment modality such as failure of CL or IG)
Assess overall patient satisfaction of patients treated with Closed Loop (CL)
Describe patients' overall experience of their treatment modality(ies): \- INSPIRE questionnaire (insulin dosing systems: perceptions, ideas, reflections, and expectations), score (0-80), higher scores = more positive attitudes or greater perceived benefit/support
Time frame: Before CL/1st IG, then at 6, 12, 24 months post-CL or post 1st IG (or just before a change in treatment modality such as failure of CL or IG)
Evaluate the clinical course of diabetes treated with Closed Loop (CL) Islet Graft (IG).
Clinical evolution criteria to be reported (first occurence): HS with assistance of a third party, hypoglycaemic comas, convulsions, cardiovascular events (acute coronary syndrome (ACS), stroke, transient ischaemic attack (TIA), amputations, haemorrhage, thrombosis) cancers, ketosis, ketoacidosis, hospitalisations, infections. The data collected will be reported according to the CTCAE v6 classification (classification terminology criteria for adverse events).
Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)
Identify the factors associated with Closed Loop (CL) treatment failures (hypoglycaemia)
Identification if the "initial number of HS with assistance from a third party" prior to BF therapy is associated with the failure of BF therapy
Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)
Identify the factors associated with Closed Loop (CL) treatment failures (diabetes-related emotional distress)
Identification if the "initial level of depression/anxiety or distress related to type 1 diabetes (T1-DDS questionnaire)" is associated with the failure of BF therapy
Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)
Identify the factors associated with Closed Loop (CL) treatment failures (fear of hypoglycemia)
Identification if the "initial level of fear of hypoglycaemia (HSF questionnaire)" is associated with the failure of BF therapy
Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)
Identify the factors associated with Closed Loop (CL) treatment failures (HbA1c)
Identification if the "initial level of HbA1 (%)" si associated with the failure of BF therapy
Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)
Identify the factors associated with Closed Loop (CL) treatment failures (TBR)
Identification if the "initial level of % time below 70mg/dL" is associated with the failure of BF therapy
Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)
Describe the frequency of occurrence of severe hypoglycaemia with third-party assistance
Incidence rate of severe hypoglycaemia with assistance of a third party
Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)
Assess the medico-economic impact at 2 years of islet transplantation compared with Closed Loop (CL) therapy from the perspective of the French healthcare system.
The cost differential and the incremental cost-utility ratio (ICUR) will be analysed and expressed as the additional cost per healthy life-year gained with islet transplantation compared with CL therapy.
Time frame: At 2 years post-equipment or post-transplant
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2030, 66 months after the start.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 66 months is above that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →